Intellectual Property India Publishes Patent Application for Antibody-Drug Conjugates Targeting Egfr/C-Met And Preparation Methods And Uses Thereof

MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202617073302 A) filed by Sichuan Kelun-Biotech Biopharmaceutical Co. , Ltd. on June 12, 2026, for Antibody-Drug Conjugates Targeting Egfr/C-Met And Preparation Methods And Uses Thereof.

Inventors include Zheng, Yong; Tian, Qiang; Lei, Dongmei; Di, Yanshu; Zhou, Yuehua; Hu, Ruibin; Long, Hu Number; Pu, Yuzhi; Yuan, Xiaoxi; Song, Hongmei; Tan, Miao; Tan, Xiangyang; and Ge, Junyou.

The application for the patent was published on July 10, 2026, under issue no. 28/2026.

Abstract: Antibody-drug conjugates (ADC) useful for preventing, treating, and/or acting as an adjuvant in treating c-MET and/or EGFR-related diseases are disclosed. The ADCs comprise a bispecific antibody or antigen-binding fragment thereof comprising an arm specific for binding to EGFR and an arm specific for binding to c-MET conjugated to a cytotoxic drug.

Disclaimer: Curated by HT Syndication.